Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

NCT07286942 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: apalolimab and toripalimab (QL1706)

Sponsor

Jiangsu Cancer Institute & Hospital